InvestSMART

Neurotech International Limited (ASX:NTI)

ALERT: Price-sensitive ASX Announcement for NTI
Current share price for NTI : $0.016 0.002 (14.29%)+
Announcement
Release
29 Aug 2025 12:38PM
Price at Release
$0.014
Full Release
download
Summary
The 2025 Annual Report for Neurotech International Limited, an Australian company, summarizes their financial performance and company activities for the year ending 30 June 2025. The company reported a significant loss of $10.6 million for the year, which contributed to accumulated losses totaling $52.2 million by the year-end. Revenue was minimal at $238, while other income, largely from R&D tax refunds, was over $2.5 million. Key expenses included research costs and share-based payments. The company is focusing on drug development, particularly the NTI164 cannabinoid therapy for neurological disorders, and has engaged in agreements to expand this work, including with the Fenix Innovative Group. The report also notes the issuance of various unlisted options as part of executive remuneration and company financing strategies.
Key Points
  • Loss of $10.6 million for the financial year ended 30 June 2025.
  • Total accumulated losses reached $52.2 million.
  • Revenue was minimal at $238, with other income from R&D tax refunds exceeding $2.5 million.
  • Significant expenses included research costs and share-based payments.
  • NTI164 cannabinoid therapy development is a focus area, with agreements made with the Fenix Innovative Group.
  • Various unlisted options issued as part of executive remuneration and financing strategies.
  • The annual report complies with the Corporations Act 2001.
  • Key remuneration disclosures for directors and executives are provided.
  • The company is not currently engaged in any on-market buy-back schemes.
  • Net assets decreased to $2.95 million from $11.9 million the previous year.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.